#United States #biotechnology #Salt Lake City #DNA Sequencing #Resonant

Resonant Achieves a New Milestone in Biotechnology Awards

On November 7, 2025, Resonant, a subsidiary of Renew Biotechnologies, proudly announced its victory in the esteemed BioTech Breakthrough Awards, earning the title of "DNA Sequencing Innovation Of The Year." This recognition underscores the innovative solutions Resonant is bringing to the diagnosis and monitoring of neurodegenerative diseases, an area that has been historically challenging for the medical community.

Transforming Diagnosis in Neurodegenerative Diseases

Resonant's groundbreaking technology hinges on a novel blood test that leverages next-generation sequencing, providing an unprecedented insight into active brain injuries. The platform is adept at identifying DNA fragments released by dying neurons and glial cells, which are then traced back to their cellular origins. This innovative approach allows for the immediate detection of neurodegeneration markers through a simple blood draw, making it a practical solution for patients and healthcare providers alike.

By utilizing native-read nanopore sequencing technology, Resonant directly measures methylation levels (5mC and 5hmC) without undergoing bisulfite conversion or PCR amplification. This enhances the accuracy by preserving true biological signals. Moreover, the developed methylome atlas effectively maps the fragmented DNA to distinct cell types, such as cortical neurons, dopaminergic neurons, and spinal motor neurons, thereby allowing clinicians to assess the specific type of cellular injury with remarkable precision.

A Rapid Response to Clinical Needs

The implications of Resonant's innovative blood test are significant. Within weeks of a singular blood draw, it can track changes in various central nervous system (CNS) cell populations, enabling healthcare providers and researchers to see real-time responses from targeted cell types. This rapid turnaround offers clinicians the ability to make informed decisions swiftly, enhancing the overall management of neurodegenerative diseases.

"The crux of Resonant’s development is the lack of accessible diagnostic tools for assessing active neurodegeneration. Our blood-based cfDNA assay directly correlates signals from dying cells to measurable data that informs diagnosis and tracks disease progression," stated Chad Pollard, the co-founder and CEO of Resonant. This advancement not only simplifies the diagnostic process but also mitigates the burden and anxiety often felt by patients undergoing invasive procedures.

Expanding Horizons in Neuroscience

Resonant's potential extends beyond its current capabilities. The platform is designed to expand, incorporating additional neuronal and glial subtypes into its brain methylation atlas. This growth is poised to enhance its sensitivity and resolution without altering the existing patient experience, identifying more nuanced insights about neurodegenerative processes.

The ability to link biomarker changes directly to disease mechanisms — such as alterations in cortical neurons for Alzheimer’s, changes in dopaminergic neurons for Parkinson’s, and spinal motor neuron degradation in ALS — sets a foundational standard for future research and therapeutic interventions.

As Resonant’s platform evolves, it aims to redefine how neurodegenerative diseases are diagnosed and treated, fostering a more personalized approach to patient care.

Recognition in the Biotech Arena

The BioTech Breakthrough Awards are pivotal in acknowledging exceptional contributions to the biotechnology sector by recognizing exemplary products, services, and companies from around the world. This year's competition attracted thousands of nominations across more than 15 nations, emphasizing the significance of rapid advancements in life sciences.

Bryan Vaughn, Managing Director at BioTech Breakthrough, remarked, "Resonant’s innovation brings forth a much-needed solution in the neurodegenerative space. The ability to visualize active CNS injury through a simple blood test provides a scalable, clinically relevant measure of degeneration that could revolutionize treatment approaches."

A Vision for the Future

About Resonant: Dedicated to pioneering advancements in the diagnosis and monitoring of neurodegenerative diseases, Resonant envisions a future where brain health is not merely a concept, but a measurable and actionable reality. By continuously integrating early molecular insights with clinical research, they strive to enhance patient outcomes and spearhead therapeutic progress in Alzheimer’s, Parkinson’s, and other complex neurological conditions.

In conclusion, Resonant's achievement is far more than an award; it symbolizes a significant step toward a future where early diagnosis and tailored treatment for neurodegenerative diseases could become a reality, transforming the landscape of patient care in the process.